Cargando…

The Future of Lung Cancer Screening: Current Challenges and Research Priorities

Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Burzic, Amna, O’Dowd, Emma L, Baldwin, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859535/
https://www.ncbi.nlm.nih.gov/pubmed/35210860
http://dx.doi.org/10.2147/CMAR.S293877
_version_ 1784654482282381312
author Burzic, Amna
O’Dowd, Emma L
Baldwin, David R
author_facet Burzic, Amna
O’Dowd, Emma L
Baldwin, David R
author_sort Burzic, Amna
collection PubMed
description Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose computed tomography, in people at higher risk of the condition reduces their mortality. Many countries are now making progress with implementing programmes, although some have concerns about cost-effectiveness. Lung cancer screening is complex, and many factors influence clinical and cost-effectiveness. It is important to develop strategies to optimise each element of the intervention from selection and participation through optimal scanning, management of findings and treatment. The overall aim is to maximise benefits and minimise harms. Additional integrated interventions must include at least smoking cessation. In this review, we summarize the evidence that has accumulated to guide optimisation of lung cancer screening, discuss the remaining open questions about the best approach and identify potential barriers to successful implementation.
format Online
Article
Text
id pubmed-8859535
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88595352022-02-23 The Future of Lung Cancer Screening: Current Challenges and Research Priorities Burzic, Amna O’Dowd, Emma L Baldwin, David R Cancer Manag Res Review Lung cancer is the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure. Over the last two decades, evidence has accumulated to show that early detection of lung cancer, using low-radiation dose computed tomography, in people at higher risk of the condition reduces their mortality. Many countries are now making progress with implementing programmes, although some have concerns about cost-effectiveness. Lung cancer screening is complex, and many factors influence clinical and cost-effectiveness. It is important to develop strategies to optimise each element of the intervention from selection and participation through optimal scanning, management of findings and treatment. The overall aim is to maximise benefits and minimise harms. Additional integrated interventions must include at least smoking cessation. In this review, we summarize the evidence that has accumulated to guide optimisation of lung cancer screening, discuss the remaining open questions about the best approach and identify potential barriers to successful implementation. Dove 2022-02-16 /pmc/articles/PMC8859535/ /pubmed/35210860 http://dx.doi.org/10.2147/CMAR.S293877 Text en © 2022 Burzic et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Burzic, Amna
O’Dowd, Emma L
Baldwin, David R
The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title_full The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title_fullStr The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title_full_unstemmed The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title_short The Future of Lung Cancer Screening: Current Challenges and Research Priorities
title_sort future of lung cancer screening: current challenges and research priorities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859535/
https://www.ncbi.nlm.nih.gov/pubmed/35210860
http://dx.doi.org/10.2147/CMAR.S293877
work_keys_str_mv AT burzicamna thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities
AT odowdemmal thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities
AT baldwindavidr thefutureoflungcancerscreeningcurrentchallengesandresearchpriorities
AT burzicamna futureoflungcancerscreeningcurrentchallengesandresearchpriorities
AT odowdemmal futureoflungcancerscreeningcurrentchallengesandresearchpriorities
AT baldwindavidr futureoflungcancerscreeningcurrentchallengesandresearchpriorities